Zachary Zubulake

Before GMP qualification begins, Halo Pharma opened its new sterile fill-finish manufacturing platform to a limited preview, with 

 getting a look inside the production suite and insights from some of the innovators bringing it to operation. Built to support sterile injectable manufacturing from clinical development through commercial production, the new platform combines Groninger filling technology with integrated SKAN isolators and ready-to-use formats from Schott, Stevenato, and Gerresheimer, covering prefilled syringes (0.5–10 mL), vials (2–30 mL), and cartridges (1–5 mL). Modern contamination control strategies support current aseptic manufacturing expectations, giving Halo a flexible platform for both clinical-scale and commercial sterile injectable programs.

Lee Karras CEO, Halo Pharma ties the move to US injectable capacity along with an introduction to Halo’s new sterile fill-finish platform before GMP qualification

Three Formats, One Platform: Halo's New Sterile Fill-Finish Line

Lee Karras, group CEO, Halo Pharma, frames the new sterile fill-finish investment as a response to capacity constraints across the domestic injectable supply chain, noting that customers absorb tariff impacts more directly than does Halo. He says onshoring supports both supply security and FDA quality expectations, adding, "We think there needs to be more domestic manufacturing, especially on the injectable side of the business."

The platform marks Halo's first foray into filling syringes, vials, and cartridges. Karras says the timing reflects a domestic injectable supply chain already operating at capacity, and described the asset as more modern than much of the installed base customers have relied on historically.

Karras also discusses Halo's agreement with Apotex, announced in April 2026,

 which he characterized as securing an anchor customer with existing products in need of a US source, a deal expected to trigger an FDA inspection early in the platform's life. He tied the investment to Halo's broader portfolio strategy, saying, "We're the only domestic source that produces oral solids, liquids, injectables, and blow-fill-seal products in one network of plants." He adds that Halo's narcotics manufacturing capability is a distinguishing attribute.

Karras says Halo plans to focus on high-value generics and narcotics that require domestic production, alongside specialized branded products, including a push into personalized medicine and gene therapy, where he says the flexibility of Halo's injectable capabilities could support smaller-batch, specialized manufacturing.


Apotex Announces Strategic U.S. Sterile Filling Partnership with Halo Pharmaceutical

Videos

Bristol-Myers Squibb’s new facility is a part of a $40 billion commitment the company pledged to invest in research and development, technology and domestic manufacturing | Image Courtesy of Bristol-Myers Squibb

Bristol Myers Squibb has selected Houston, Texas, as the site for a new manufacturing campus representing an investment of approximately $2.3 billion.

 The roughly 600,000-square-foot facility, to be located at Generation Park, is expected to create nearly 500 skilled jobs once operational and is designed to expand in scale and capability over time.

The Houston site is part of a broader $40 billion commitment the company has pledged to invest in the US over five years, spanning research and development, technology, and domestic manufacturing.

 The announcement follows a wave of similar reshoring and capacity-expansion announcements from large biopharmaceutical manufacturers, as companies weigh supply chain resilience, unstable tariff policy, and proximity to US commercial markets against the cost advantages of overseas production.

What Makes the Facility's Design Notable?

The campus is described as modular and multi-modal, meaning its manufacturing infrastructure can be reconfigured and expanded as the company's pipeline evolves.

Rather than being built for a single product type, the site is intended to support small molecules, biologics, and antibody-drug conjugates within the same footprint, covering drug product and finished goods manufacturing from late-stage development through commercial launch.

This flexible platform approach reflects a broader industry shift away from single-purpose plants toward facilities that can pivot across modalities without a full rebuild.

 As therapeutic pipelines increasingly mix biologics, conjugates, and small molecules, the ability to bring new capacity online within an existing campus, rather than commissioning a new one, has become a meaningful factor in how companies plan capital deployment and manage time-to-market.

Karin Shanahan, Chief Supply Chain and Operations Officer, Bristol Myers Squibb, said in a press release,

"This facility is designed to deliver the speed, quality, and reliability that patients depend on, combining flexible, modular manufacturing with advanced digital capabilities to ensure consistent supply across multiple modalities. It strengthens our ability to operate with resilience and positions us to reliably deliver medicines to patients today while adapting future demands."

Construction and site build-out are expected to run through 2030, with the facility intended to scale well beyond its initial configuration as demand grows. The project may offer a valuable case study in how large-scale, multi-modal capacity planning is being approached at a moment when supply chain resilience remains a persistent industry priority.

How Does This Fit Into the Broader Reshoring Trend?

The Houston campus reflects a wider pattern reshaping US drug manufacturing.

 Federal tariff policy and state-level incentives have pushed pharmaceutical companies to pledge roughly $370 billion in domestic manufacturing and research investment over five years, with states competing directly for projects. Texas has expanded its research and development tax credit to attract advanced manufacturing, while North Carolina is phasing out corporate income tax to compete for the same investment.

 Industry analysts note that returns on these facilities increasingly depend on digital integration, connecting equipment data and workforce activity into unified operational systems rather than treating capacity expansion as a purely physical build-out.

Bristol Myers Squibb advances U.S. manufacturing investment with new $2.3 billion campus in Houston, Texas. Press Release.

https://news.bms.com/news/corporate-financial/2026/Bristol-Myers-Squibb-Advances-U-S--Manufacturing-Investment-with-New-2-3-Billion-Campus-in-Houston-Texas/default.aspx

Eschbach A. Reshoring pharma: how tariffs and tech are reshaping the next chapter. Forbes. Published March 25, 2026. 

https://www.forbes.com/councils/forbestechcouncil/2026/03/25/reshoring-pharma-how-tariffs-and-tech-are-reshaping-the-next-chapter/

North Carolina enacts corporate income tax phase-out.

https://www.pwc.com/us/en/services/tax/library/north-carolina-enacts-corporate-income-tax-phaseout.html

Articles

Bristol Myers Squibb will build a ~$2.3B, ~600,000-square-foot manufacturing campus at Generation Park in Houston, targeting nearly 500 skilled jobs and scalable expansion through 2030. The site aligns with a broader $40B, five-year US investment spanning R&D, technology, and manufacturing amid heightened focus on supply-chain resilience, tariff uncertainty, and market proximity. Notably, the campus is modular and multi-modal, designed to flex across small molecules, biologics, and ADCs, supported by advanced digital capabilities to maintain consistent supply from late-stage development through commercialization.

BMS's Investing $2.3B into its Houston campus signals a shift toward flexible, multi-modal manufacturing. 

BMS Bets on Flexible Capacity With $2.3B Texas Campus

The Implications of Orzeyful (oveporexton) approval by the FDA

The FDA approved Orzeyful (oveporexton) tablets on August 5, 2026 for the treatment of narcolepsy type 1 in adults, marking the first therapy designed to treat the disorder as a unified condition rather than a collection of separate symptoms.

 It is also the first approved medicine that works by directly restoring signaling from orexin, the brain chemical whose loss causes the disease.

Narcolepsy type 1 affects an estimated 1 in 2000 people in the United States. It results from the destruction of brain cells that produce orexin, a messenger responsible for regulating wakefulness, sleep, and muscle tone.

 Its absence produces a cluster of disabling symptoms: excessive daytime sleepiness, cataplexy, sleep paralysis, hallucinations at the edge of sleep, and fragmented nighttime rest. Existing treatments have historically addressed these symptoms individually, using stimulants to manage wakefulness or other agents to blunt cataplexy, without correcting the underlying biological deficit.

Why Does the Mechanism Matter More than Symptom Management?

 Rather than masking symptoms, it activates the same brain receptor that orexin itself would normally stimulate, restoring a signal the body can no longer produce on its own. In 2 randomized, double-blind, placebo-controlled 12-week trials enrolling 273 adults, patients taking the 2 mg dose showed improved ability to stay awake during the day relative to placebo, along with reduced daytime sleepiness, fewer cataplexy episodes, and measurable improvement across the disorder's broader symptom profile. The most frequently reported side effects were insomnia, increased urinary frequency and urgency, and excess saliva production, with a low rate of treatment discontinuation due to adverse effects.

Tiffany Farchione, MD, director of the Division of Psychiatry in the FDA's Center for Drug Evaluation and Research, framed the approval as a shift in treatment philosophy, in a press release,

For too long, people with narcolepsy type 1 have had to manage a complex, lifelong neuropsychiatric condition with treatments that only address pieces of it. This new drug is the first medicine that impacts the underlying biology of the disease, treating narcolepsy type 1 as a whole,” she stated.

What Should Development and Manufacturing Teams Take from This Approval?

This approval is a signal of where central nervous system drug development could be headed, toward therapies engineered against a disorder's specific molecular deficit rather than its downstream symptoms.

 Orexin receptor agonism has been an area of longstanding scientific interest, and a first approved product in this class offers a validated mechanism that other developers working in broader neuropsychiatric indications should study closely, both for its clinical trial design and its regulatory pathway. The drug's route through Breakthrough Therapy Designation and Priority Review also reflects how the agency is pushing to expedite review for therapies addressing serious, underserved conditions where no mechanistically targeted option previously existed.

There are practical downstream considerations as well.

 Orzeyful has been recommended for scheduling under the Controlled Substances Act, meaning it cannot be lawfully marketed until the Drug Enforcement Administration finalizes that scheduling decision. The product also carries a labeled interaction with strong CYP3A inhibitors, underscoring the ongoing importance of drug-interaction data in supporting safe use once a novel mechanism reaches the market. Its safety and effectiveness have not been established in patients under 18 years of age, leaving pediatric development as an open question for the orexin receptor agonist class going forward.

How Are Patients and Advocates Responding to the Approval?

Patient advocacy groups have framed the approval as a turning point for a community long limited to symptom-focused treatment.

 Julie Flygare, president and CEO, Project Sleep and a person living with narcolepsy type 1, said in a press release,

 "For those of us living with narcolepsy type 1, symptoms reshape everyday life and extend far beyond what most people understand about the condition. Orzeyful's approval is a historic moment that expands our treatment choices and gives me great hope for the future and for our community." 

FDA approves first drug to treat the full range of narcolepsy type 1 symptoms. US Food and Drug Administration. News Release. August 5, 2026. 

https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-treat-full-range-narcolepsy-type-1-symptoms

U.S. FDA approves Takeda’s ORZEYFUL™ (oveporexton), the first and only medicine to treat the underlying cause of narcolepsy type 1. Business Wire. August 5, 2026. 

https://www.businesswire.com/news/home/20260805760759/en/U.S.-FDA-Approves-Takedas-ORZEYFUL-oveporexton-the-First-and-Only-Medicine-to-Treat-the-Underlying-Cause-of-Narcolepsy-Type-1

FDA approval of oveporexton (Orzeyful) for adult narcolepsy type 1 introduces the first therapy positioned to treat the disorder as a unified pathophysiologic entity by directly restoring orexin signaling via receptor agonism. In two 12-week randomized, double-blind, placebo-controlled trials (n=273), the 2 mg dose improved wakefulness and reduced daytime sleepiness and cataplexy, with broader symptom benefit. Common adverse events included insomnia, urinary frequency/urgency, and hypersalivation, with few discontinuations. Regulatory acceleration and pending DEA scheduling shape launch timing.

The FDA approved the first orexin receptor agonist for narcolepsy type 1, which validates a new mechanism-driven approach shaping CNS drug development and regulatory pathways.

Why the Orzeyful Approval Matters Beyond One Drug Class

Pathos AI agreed to pay $125 million upfront to a subsidiary of Alphamab Oncology for rights to an experimental treatment for triple-negative breast cancer, the company announced on July 3, 2026.

The agreement gives Pathos AI research, development, manufacturing, and commercialization rights to the antibody-drug conjugate (ADC) candidate, known as JSKN016, everywhere except Taiwan, Macau, Hong Kong, and mainland China.

Beyond the initial payment, Jiangsu Alphamab Biopharmaceutical is eligible for additional development and commercialization milestone payments.

 Combined with the upfront sum, the total deal value could reach as much as $2.09 billion if all milestones are met.

Why Is Triple-Negative Breast Cancer a Priority Target?

Triple-negative breast cancer is an aggressive subtype that tends to grow and spread more quickly than other forms of the disease, and it comes with fewer treatment options for patients.

 It accounts for roughly 10% to 15% of all breast cancer diagnoses. Current treatment options include Merck's Keytruda and Gilead's Trodelvy, both of which have shown measurable benefit in reducing recurrence risk in recent trials. JSKN016 is currently in a late-stage trial for triple-negative breast cancer, along with earlier-stage studies evaluating its use in other tumor types.

Iker Huerga, chief executive, Pathos AI, said in a press release,

 "JSKN016 is a next-generation bispecific ADC with the potential to address significant unmet need across a range of solid tumors, and we are excited to advance it in partnership with Alphamab. This program was identified through Foundry, the same platform that continues to guide portfolio decisions across our clinical pipeline. This collaboration reflects our shared commitment to bringing differentiated therapies to patients."

JSKN016 is a bispecific ADC that targets both TROP2 and HER3 receptors on tumor cells, using site-specific glycosylation to produce a homogeneous conjugate with a drug-to-antibody ratio of four.

 The molecule blocks associated signaling pathways and releases topoisomerase I inhibitors through cellular endocytosis. Pathos AI identified the asset through Foundry, its internal platform that applies large-scale data analysis to portfolio decisions, making JSKN016 the fourth clinical-stage program added through that process. It joins 3 other pipeline candidates targeting prostate cancer, multiple myeloma, lung cancer, and breast cancer, reflecting a broader push toward AI-assisted asset selection in oncology development.

What Does this Deal Signal for Drug Development?

Licensing agreements of this structure and scale are becoming a defining feature of oncology drug development, and this transaction offers a useful window into how that dynamic is playing out.

 Rather than building an oncology pipeline entirely through internal discovery, companies are increasingly securing rights to clinical-stage assets originating from biopharmaceutical developers in China, where a growing share of novel oncology candidates are now entering trials. This pattern carries direct implications for development and manufacturing: cross-border licensing deals often require technology transfer, harmonization of manufacturing processes across regulatory jurisdictions, and coordination between original developers and new rights holders on quality systems and supply chain planning.

The milestone-heavy structure of the agreement also reflects how risk is increasingly distributed across the development timeline in oncology licensing deals, with a comparatively modest upfront payment tied to a much larger sum contingent on clinical and regulatory progress.

 That structure places pressure on development and manufacturing functions to execute efficiently at each stage, because delays or setbacks can directly affect deal economics for both parties.

For professionals tracking the competitive landscape in triple-negative breast cancer treatment, the entry of another asset into late-stage development adds to a field that already includes established options.

 As more candidates advance through clinical trials, manufacturing scale-up, quality compliance, and supply chain readiness will become increasingly important differentiators, particularly for smaller or newer entrants competing against companies with established commercial infrastructure.

Pathos AI to license experimental breast cancer drug from China’s Jiangsu Alphamab Biopharmaceutical. 

https://www.reuters.com/legal/litigation/pathos-ai-license-experimental-breast-cancer-drug-chinas-jiangsu-alphamab-2026-08-04/

Pathos AI enters global licensing agreement with Alphamab Oncology on JSKN016, a First-in-Class TROP2/HER3 Bispecific ADC. 

https://www.businesswire.com/news/home/20260803012674/en/Pathos-AI-Enters-Global-Licensing-Agreement-with-Alphamab-Oncology-on-JSKN016-a-First-in-Class-TROP2HER3-Bispecific-AD

Pathos AI secured global rights (ex-China/Taiwan/HK/Macau) to Alphamab Oncology’s late-stage triple-negative breast cancer ADC, JSKN016, for $125 million upfront and up to $2.09 billion total via milestones. The asset is a next-generation bispecific ADC targeting TROP2 and HER3 with a defined DAR of four and Topo I payload release following endocytosis. The transaction underscores escalating reliance on China-originated clinical-stage oncology assets, with risk shifted to milestone-based payments and heightened emphasis on tech transfer, manufacturing harmonization, and supply-chain execution.

Pathos AI's $2.09 billion license for Alphamab's TNBC drug JSKN016 signals rising cross-border oncology deals and manufacturing coordination demands.

Triple-Negative Breast Cancer Deal Signals Oncology Licensing Shift

Pharma's 2026 predictions revisited: AI tools have arrived, but organizational readiness, data governance, and regulatory gaps now limit real-world impact.

H1 2026 in Review: AI Adoption, Onshoring, and Data Gaps

Six months after industry experts laid out their predictions for 2026, many of those experts return to see what's tracking, what's shifted, and what it means for drug development and manufacturing professionals in H2.

The throughline across every prediction is the same: the technology moved faster than the organizations meant to use it. Manish Garg, serialization, regulatory compliance, and track and trace expert, who framed AI in drug discovery as a speed play back in December 2025, now sees the real story as strategic. As he puts it, "What's become clearer in the first half of 2026 is that the more meaningful shift is happening at the strategy level, not just the speed level."

That readiness gap shows up in regulatory enforcement, too. Mike Stenberg, LGM Pharma, points to FDA's first warning letter specifically citing improper AI use in manufacturing “with a major oversight related to specifications and procedures."

On the data side, Remco Munnik, Arcana Life Sciences, argues that Europe's database-driven submissions push is exposing a more fundamental problem than technology adoption, adding that "AI only works when the underlying data governance is solid."

Supply chain predictions largely held, with Campbell Bunce, Abzena, confirming that selective US onshoring and a biologics surge, including ADCs and antibody oligo conjugates, are playing out roughly as forecast. Meanwhile, Megha Sinha frames the year's real headline plainly: "the technology has now arrived, and the binding constraint turns out to be the organizational readiness, the employee sentiment, and the data."

Is Organizational Readiness Pharma's Real AI Barrier in 2026?

Back in December 2025, several industry leaders staked out predictions for what 2026 would bring to drug development and manufacturing. Now, at the midpoint of the year, many of those experts return to see how their predictions held up. They find a pattern showing up across nearly every prediction: the tools arrived quickly, but the organizations meant to run them didn't catch up nearly as fast.

When referring to AI in drug discovery, Manish Garg, industry expert, originally called it a race for speed. Six months in, he's revised that read entirely, telling 

 "What's become clearer in the first half of 2026 is that the more meaningful shift is happening at the strategy level, not just the speed level."

Regulators are catching the same gap from the enforcement side. Mike Stenberg, LGM Pharma, flags a milestone warning letter as proof that the oversight is already here. "Earlier this year, FDA issued its first warning letter that specifically cites improper use of AI in manufacturing with a major oversight related to specifications and procedures," he says.

Underneath both trends sits a harder problem: data. Remco Munnik, Arcana Life Sciences, tracking Europe's shift toward database-driven submissions, put it as "AI only works when the underlying data governance is solid."

Elsewhere, the forecasts are holding steady; US onshoring is advancing selectively, biologics approvals are climbing, and Campbell Bunce, Abzena, says the industry's trajectory matches almost exactly what was predicted six months ago. Megha Sinha sums up where that leaves manufacturers, saying, "the technology has now arrived, and the binding constraint turns out to be the organizational readiness, the employee sentiment, and the data."

The full picture, including what each expert got right, what they missed, and where they're recalibrating for H2, is best heard in their own words.

(Free, 30-second registration required for new users)